Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 11, 2013

View Archived Issues

Ono Pharmaceutical reports highlights of second quarter of fiscal 2013

Lundbeck reflects on active third quarter 2013

Nuvilex acquires rights to cellulose-based live-cell encapsulation technology for diabetes

Anti-LOXL2 antibody suppresses collagen cross-linking and fibrosis progression in vivo

Advanced Proteome Therapeutics achieves milestone in cancer program

University of Virginia to study PTP-01 as imaging agent for pancreatic cancer

Phase II clinical data demonstrate efficacy for an antibody to treat adipocytic sarcoma

ACEA Biosciences' AC-0025 shows antiarthritic activity in vivo

Novel tyrosine-protein kinase inhibitors patented by Advinus Therapeutics

Dainippon Sumitomo Pharma prepares new 11-beta-HSD1 inhibitors

New cathepsin S inhibitors disclosed by Astellas Pharma

Biodel advances ultra-rapid-acting insulin product BIOD-531 into clinical development

New fusion proteins to reactivate apoptosis in TRAIL/Apo-2L-resistant cancer cells described

New Hsp70 inducers presented by scientists in the Netherlands

Drug repositioning detects efficacy of drugs for malaria

Immuron cleared to conduct trial of IMM-124-E for alcoholic steatohepatitis

Eisai and Broad Institute to develop new drugs for neglected tropical diseases

Discovery Laboratories begins U.S. launch of Surfaxin

CereSpir acquires rights to cognitive impairment treatment candidate

FDA clears CERC-301 for phase II study in major depression

Grifols to acquire Novartis' transfusion diagnostics unit

GW Pharmaceuticals initiates phase Ib/IIa study of cannabinoids for glioblastoma multiforme

FDA approves Aptiom as adjunctive treatment for partial-onset seizures

Eisai launches Aciphex Sprinkle in U.S.

Shire to acquire ViroPharma

Salix Pharmaceuticals to acquire Santarus

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...